A body of evidence supports that excitatory amino acid systems, particularly glutamatergic one, participate in morphine dependence and naloxone-precipitated withdrawal. In this study, we examined the involvement of glial glutamate transporters, GLT-1 and GLAST, in them. Rats were rendered morphine-dependent by subcutaneous implantation of two 75 mg morphine pellets for 5 days. Intracerebroventricular administration of DL-threo-b-benzyloxyaspartate, a glutamate transporter inhibitor signiˆcantly facilitated various naloxone-precipitated withdrawal signs. By northern blot analysis, the expression of GLT-1 mRNA was found to decrease signiˆcantly in the striatum and thalamus of morphinedependent rats, and to increase signiˆcantly in the striatum 2 hr after the naloxone-precipitated withdrawal. On the other hand, there were no signiˆcant changes in GLAST mRNA levels in any brain regions. In vivo microdialysis experiments revealed that the extracellular glutamate levels was elevated in the striatum and nucleus accumbens, in which the changes of GLT-1 mRNA level were observed, during naloxone-precipitated morphine withdrawal. In cultured astrocytes, the expression of GLT-1 mRNA was regulated by agents activating the cAMP pathway, as well as b-adrenergic agonist and dopamine, but not morphine. These results suggest that the changes of GLT-1 expression, which alter the glutamate uptake and aŠect the glutamatergic transmission e‹ciency, play a role in the development of morphine dependence and the expression of morphine withdrawal.
Animals in placebo-treated and morphine-dependent group were implanted with two placebo or morphine pellets for 5 days, respectively. For the morphine-withdrawal group, the morphine-dependent rats were intraperitoneally administered with naloxone (3 mg/kg). Northern blot analysis was conducted using a 32 P-labeled rat GLT-1 or GLAST antisense RNA probes. In each region, the expression of GLT-1 or GLAST mRNA in placebo-treated rats was assigned a value of 100％. Data are presented as the means ± S.E.M. of the percentage of the placebo-treated group of 4-6 separate experiments.  p＜0.05,   p＜0.01 compared with the placebo-treated group; ♯ p＜0.05 vs. morphine-dependent group (Mann-Whitney U-test).
Fig. 3. EŠect of Naloxone-Precipitated Withdrawal on Extracellular Glutamate Concentration in Rat Striatum (a) and Nucleus Accumbens (b)
Morphine-dependent rats were intraperitoneally administered with naloxone (3 mg/kg) at the time zero indicated (arrow). Dialysates were collected at 15 min intervals for the determination of glutamate levels. Data are expressed as the means ± S.E.M. of the percentage of the basal values calculated as an average of three consecutive stable dialysates before naloxone administration. n＝3-5. The rat cultured astrocytes were incubated with acethylcholine, isoproterenol, dopamine, 5-hydroxytryptamine (5-HT), g-aminobutyric acid (GABA), L-glutamate and ATP at the concentration of 1 mM for 24 hr (upper) and 48 hr (lower). The cells were harvested and the total RNA was extracted. Northern blotting was conducted using a 32 P-labeled rat GLT-1 antisense RNA probe. 
